Natalizumab in clinical practice: Managing the risks, enjoying the benefits

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 11, 2014, Pages 1181-

  Aktas, Orhan ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; MONOCLONAL ANTIBODY; NATALIZUMAB;

DRUG EFFECTS; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTEGRIN ALPHA4; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84896422979     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-307355     Document Type: Note

References (5)

1. Rudick R, Polman C, Clifford D, et al. Natalizumab: bench to bedside and beyond. JAMA Neurol 2013;70:172-82.
2. Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014;85:1190-7.
3. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8:254-60.
4. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011;17:970-9.
5. Hartung H, Aktas O. Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurol 2011;10:293-5.